The Central Player in Ferroptosis Defense

For years after ferroptosis was discovered in 2012, one enzyme stood at the center of understanding how cells prevent this form of death: GPX4 (Glutathione Peroxidase 4). While we now know that cells employ multiple ferroptosis defense systems—including FSP1-CoQ10 and GCH1-BH4—GPX4 remains the most critical and best-characterized guardian against iron-dependent cell death.

GPX4 is unique among cellular enzymes in its ability to directly reduce lipid hydroperoxides embedded in cell membranes. This specialized function makes it the primary line of defense against the lipid peroxidation that drives ferroptosis. When GPX4 fails—whether through direct inhibition, depletion of its cofactor glutathione, or overwhelming oxidative stress—ferroptosis rapidly follows.

Understanding GPX4 is essential to understanding ferroptosis. This enzyme represents the mechanistic link that explains how diverse triggers (cysteine depletion, glutathione loss, direct GPX4 inhibition) converge on a common pathway leading to ferroptotic cell death.

What is GPX4?

GPX4 (Glutathione Peroxidase 4), also known as phospholipid hydroperoxide glutathione peroxidase (PHGPx), is a selenoprotein enzyme—meaning it contains the rare amino acid selenocysteine in its active site. GPX4 belongs to the glutathione peroxidase family, which includes eight members (GPX1-8) in mammals, but GPX4 is the only one capable of reducing complex lipid hydroperoxides within membranes.

The GPX Family:

• GPX1-3: Primarily reduce hydrogen peroxide (H₂O₂) and simple hydroperoxides in aqueous environments
• GPX4: Uniquely reduces phospholipid hydroperoxides (PL-OOH) in membranes
• GPX5-8: Various specialized functions in reproduction, development, and metabolism

GPX4’s distinctive ability to access and reduce membrane-embedded lipid hydroperoxides—rather than just water-soluble substrates—is what makes it indispensable for ferroptosis prevention.

The Discovery of GPX4’s Role in Ferroptosis

GPX4 was discovered and characterized decades before ferroptosis was identified, but its connection to ferroptosis emerged through converging lines of evidence:

Early Clues (1980s-2000s):

• GPX4 was identified as a selenoprotein that could reduce lipid hydroperoxides
• Genetic studies showed GPX4 was essential—complete GPX4 knockout was embryonically lethal in mice
• GPX4 overexpression protected cells from oxidative stress-induced death

The Ferroptosis Connection (2014): Multiple research groups independently made the crucial discovery linking GPX4 to ferroptosis:

• José Pedro Friedmann Angeli and Marcus Conrad showed that conditional GPX4 deletion triggered a form of cell death with all the hallmarks of ferroptosis
• Wei Gu and Xuejun Jiang demonstrated that RSL3—one of the original ferroptosis-inducing compounds—kills cells by directly inhibiting GPX4
• Brent Stockwell’s group confirmed that GPX4 inhibition is sufficient to induce ferroptosis

These landmark 2014 papers established GPX4 as the central regulator of ferroptosis, providing the mechanistic explanation for how erastin and RSL3 kill cells.

How GPX4 Works: The Molecular Mechanism

GPX4 prevents ferroptosis by catalyzing a crucial antioxidant reaction:

The Reaction:

Phospholipid-OOH + 2 GSH → Phospholipid-OH + GSSG + H₂O

Where:

• Phospholipid-OOH = Lipid hydroperoxide (toxic, membrane-damaging)
• GSH = Reduced glutathione (cellular antioxidant, GPX4’s cofactor)
• Phospholipid-OH = Lipid alcohol (non-toxic)
• GSSG = Oxidized glutathione (can be recycled back to GSH)

Step-by-Step:

1. Substrate Recognition: GPX4 recognizes phospholipid hydroperoxides in cell membranes—oxidized lipids containing reactive peroxide groups (-OOH)
2. Active Site Chemistry: The selenocysteine residue in GPX4’s active site is oxidized by the lipid hydroperoxide, reducing the peroxide to a harmless alcohol (-OH)
3. Glutathione Regeneration: Two glutathione molecules (GSH) reduce the oxidized selenocysteine back to its active form, themselves becoming oxidized to GSSG
4. Cycle Continuation: GPX4 is regenerated and ready for another catalytic cycle, while GSSG is recycled back to GSH by glutathione reductase

Why This Matters:

Lipid hydroperoxides are the direct executioners in ferroptosis. They damage membranes, disrupt cellular organization, and trigger cell death. By converting these toxic molecules into harmless alcohols, GPX4 continuously maintains membrane integrity and prevents ferroptosis.

The Selenocysteine Advantage

GPX4’s active site contains selenocysteine (Sec, the “21st amino acid”), rather than the more common cysteine. This seemingly small difference is actually crucial:

Selenocysteine vs. Cysteine:

• Selenocysteine has selenium (Se) instead of sulfur (S)
• Selenium is more nucleophilic (reactive) at physiological pH
• This makes selenocysteine far more efficient at the catalytic mechanism

Biological Significance:

• Selenocysteine incorporation requires special cellular machinery
• GPX4 synthesis depends on adequate dietary selenium
• Selenium deficiency can compromise GPX4 activity and increase ferroptosis susceptibility

Clinical Relevance:

• Selenium supplementation may enhance GPX4 function
• Selenium-deficient diets or conditions could sensitize to ferroptosis
• Geographic regions with low selenium in soil may have different ferroptosis-related disease risks

GPX4 Isoforms: Different Locations, Same Function

GPX4 exists in multiple isoforms produced from the same gene through alternative transcription start sites:

Cytosolic GPX4 (cGPX4):

• Most abundant form
• Localized in the cytoplasm
• Protects cytosolic membranes and organelles

Mitochondrial GPX4 (mGPX4):

• Contains an N-terminal mitochondrial targeting sequence
• Localized within mitochondria
• Protects mitochondrial membranes from lipid peroxidation
• Particularly important as mitochondria generate reactive oxygen species

Nuclear GPX4 (nGPX4):

• Localized to the nucleus
• Less well characterized
• May protect nuclear membranes and chromatin-associated structures

Sperm-Specific GPX4 (snGPX4):

• Expressed during spermatogenesis
• Essential for sperm structural integrity
• Deficiency causes male infertility
• Becomes a structural protein in mature sperm

All isoforms perform the same catalytic function—reducing lipid hydroperoxides—but their different localizations ensure comprehensive cellular protection.

The Glutathione Dependency

GPX4 cannot function without glutathione (GSH), making the entire glutathione biosynthesis and recycling pathway critical for ferroptosis defense.

The Glutathione Connection:

1. Cysteine Import: System xc⁻ imports cystine (oxidized cysteine) into cells
2. Cystine Reduction: Cystine is reduced to cysteine inside cells
3. Glutathione Synthesis: Cysteine (rate-limiting), glutamate, and glycine are assembled into GSH
4. GPX4 Cofactor: GSH serves as the reducing agent for GPX4’s catalytic cycle
5. GSH Recycling: GSSG is reduced back to GSH by glutathione reductase (using NADPH)

Vulnerability Points:

Any disruption in this pathway can compromise GPX4 function and trigger ferroptosis:

• Erastin blocks system xc⁻ → no cysteine import → GSH depletion → GPX4 can’t function
• Buthionine sulfoximine (BSO) inhibits GSH synthesis → GSH depletion → GPX4 can’t function
• RSL3 directly inhibits GPX4 → even with adequate GSH, lipid peroxides aren’t reduced

This explains the “many roads to ferroptosis” concept—different triggers ultimately converge on GPX4 failure.

Direct GPX4 Inhibitors

Several compounds have been identified that directly inhibit GPX4, providing powerful tools for research and potential cancer therapy:

RSL3 (RAS-Selective Lethal 3):

• First identified GPX4 inhibitor
• Covalently binds to GPX4’s selenocysteine
• Potent ferroptosis inducer
• Selectivity for cancer cells with RAS mutations
• Tool compound (not yet clinically developed)

ML162:

• Another direct GPX4 inhibitor
• Similar mechanism to RSL3
• Used in research settings

FIN56:

• Depletes GPX4 protein levels (rather than just inhibiting activity)
• Also affects CoQ10, providing dual ferroptosis induction

FINO₂:

• Indirectly inactivates GPX4
• Also causes iron oxidation
• Multi-targeted ferroptosis inducer

These compounds have been invaluable for:

• Proving GPX4’s central role in ferroptosis
• Studying ferroptosis mechanisms
• Identifying ferroptosis-sensitive cancers
• Developing potential cancer therapies

GPX4 Essentiality: Why Cells Can’t Live Without It

GPX4 is one of relatively few genes that are absolutely essential for mammalian life:

Embryonic Lethality:

• Complete GPX4 knockout mice die during early embryonic development
• Demonstrates GPX4 is essential for cell survival
• No other enzyme can compensate for complete GPX4 loss

Conditional Knockout Studies:

• Deleting GPX4 in specific adult tissues causes:
  • Rapid cell death with ferroptotic characteristics
  • Tissue degeneration
  • Organ failure
• Demonstrates ongoing requirement even in mature organisms

Why Essential?

• Background lipid peroxidation occurs continuously due to normal metabolism
• Even low-level oxidative stress generates lipid hydroperoxides
• Without GPX4, these accumulate to toxic levels
• Alternative pathways (FSP1, GCH1) provide backup but aren’t sufficient alone in most cells

Therapeutic Implications:

• GPX4 inhibition will kill cells—useful for cancer therapy
• Must be selective to avoid killing normal cells
• Combination with other pathway inhibitors may enhance selectivity

GPX4 in Cancer: A Double-Edged Sword

GPX4’s role in ferroptosis makes it critically relevant to cancer biology:

Cancer Cell Dependence:

Many cancer cells are particularly dependent on GPX4:

• High metabolic rate generates more oxidative stress
• Rapid proliferation requires constant membrane synthesis (lipid-rich, vulnerable)
• RAS mutations (common in cancer) may increase ferroptosis sensitivity
• Therapeutic stress (chemotherapy, radiation) increases oxidative burden

GPX4 as a Therapeutic Target:

Rationale:

• Inhibiting GPX4 selectively kills cancer cells
• Some tumors are “addicted” to GPX4—highly dependent on it for survival
• Ferroptosis may overcome resistance to traditional apoptosis-inducing therapies

Challenges:

• Selectivity: how to kill cancer without harming normal cells?
• Resistance: cancers may upregulate alternative defenses (FSP1, GCH1)
• Delivery: getting GPX4 inhibitors specifically to tumors

GPX4 in Therapy Resistance:

Some cancer cells adapt to therapies by:

• Upregulating GPX4 expression
• Enhancing glutathione synthesis
• Activating alternative ferroptosis defenses

Understanding these resistance mechanisms guides combination therapy strategies.

GPX4 in Neurodegeneration

The brain is particularly vulnerable to ferroptosis, and GPX4 plays a crucial protective role:

Why the Brain is Vulnerable:

• High lipid content (membranes, myelin)
• Abundant PUFAs in neuronal membranes
• High metabolic rate and oxygen consumption
• High iron content in certain brain regions
• Limited regenerative capacity

GPX4 in Neurodegenerative Diseases:

Alzheimer’s Disease:

• Evidence of reduced GPX4 expression in affected brain regions
• Lipid peroxidation is a hallmark of disease pathology
• GPX4 loss may contribute to neuronal death

Parkinson’s Disease:

• Dopaminergic neurons show ferroptosis markers
• Iron accumulation in substantia nigra
• GPX4 dysfunction may contribute to neurodegeneration

Huntington’s Disease:

• Mutant huntingtin may impair GPX4 function
• Ferroptosis implicated in striatal neuronal loss

Stroke and Ischemia:

• Ischemia-reperfusion triggers ferroptosis
• GPX4 activity is crucial during recovery
• Enhancing GPX4 may provide neuroprotection

Therapeutic Potential:

• Boosting GPX4 activity might slow neurodegeneration
• Selenium supplementation to support GPX4
• Genetic or pharmacological GPX4 enhancement
• Protecting GPX4 from inactivation during stress

GPX4 in Other Diseases

Ischemia-Reperfusion Injury:

When blood flow is restored after blockage (heart attack, stroke, organ transplantation):

• Sudden oxygen return triggers oxidative stress
• Lipid peroxidation overwhelms GPX4 capacity
• Ferroptosis contributes to tissue damage
• Enhancing GPX4 or providing alternative defenses may protect

Kidney Disease:

Acute Kidney Injury (AKI):

• Tubular epithelial cells undergo ferroptosis
• GPX4 expression decreases during injury
• Ferroptosis inhibitors show protective effects in animal models

Chronic Kidney Disease (CKD):

• Ongoing oxidative stress and iron accumulation
• GPX4 dysfunction may contribute to progression
• Potential therapeutic target

Liver Disease:

• Hepatocytes are vulnerable to ferroptosis during:
  • Non-alcoholic fatty liver disease (NAFLD)
  • Acetaminophen toxicity
  • Ischemia-reperfusion
• GPX4 activity modulates disease severity

Infection and Immunity:

• Some immune cells use ferroptosis to kill pathogens or infected cells
• GPX4 expression in immune cells affects immune responses
• Balance between immune function and self-protection

Regulation of GPX4

Understanding what controls GPX4 expression and activity is crucial:

Transcriptional Regulation:

Positive Regulators:

• NRF2 (nuclear factor erythroid 2-related factor 2): master antioxidant transcription factor
• ATF4 (activating transcription factor 4): stress-responsive factor
• Various other stress-response pathways

Negative Regulators:

• Some conditions or pathways suppress GPX4 expression
• Mechanisms still being elucidated

Post-Transcriptional Regulation:

mRNA Stability:

• GPX4 mRNA contains regulatory elements
• RNA-binding proteins can affect stability and translation

Selenocysteine Incorporation:

• Requires adequate selenium availability
• SECIS (selenocysteine insertion sequence) element in GPX4 mRNA
• Complex translation machinery specific to selenoproteins

Post-Translational Regulation:

Protein Stability:

• GPX4 degradation pathways
• Stabilization under certain conditions

Activity Modulation:

• Direct oxidative modifications
• Potential phosphorylation or other modifications
• Cofactor (GSH) availability

Metabolic Regulation:

• Selenium availability (dietary)
• Glutathione levels (cysteine, glutamate, glycine availability)
• Cellular redox state
• Energy status (ATP needed for GSH synthesis)

Experimental Tools and Approaches

Studying GPX4:

Genetic Approaches:

• Knockout models: Conditional GPX4 deletion in specific tissues/timepoints
• Overexpression: Increasing GPX4 to enhance protection
• Knockdown: siRNA or shRNA to reduce GPX4 levels
• CRISPR screens: Identifying GPX4-dependent processes

Pharmacological Tools:

• RSL3: Direct GPX4 inhibitor
• ML162: Alternative GPX4 inhibitor
• BSO: Blocks GSH synthesis (indirect)
• Erastin: Depletes GSH (indirect)

Measurement:

• Western blotting: Protein expression levels
• qPCR: mRNA expression
• Activity assays: Enzymatic function measurements
• Immunofluorescence: Cellular localization
• Mass spectrometry: Protein modifications

Ferroptosis Readouts:

• Lipid peroxidation (C11-BODIPY, MDA, 4-HNE)
• Cell viability (in presence vs. absence of ferroptosis inhibitors)
• Morphology (electron microscopy showing mitochondrial changes)

GPX4 and the Evolution of Ferroptosis Understanding

GPX4’s role illustrates the evolution of ferroptosis research:

2012-2014: The Mystery

• Ferroptosis discovered but mechanism unclear
• How do erastin and RSL3 kill cells?

2014: The Breakthrough

• GPX4 identified as the key target
• Mechanistic clarity: GPX4 failure → lipid peroxidation → ferroptosis

2016-2017: Complexity

• ACSL4/LPCAT3 determine lipid vulnerability
• Not just GPX4 activity but also substrate composition

2019-2020: Redundancy

• FSP1-CoQ10 and GCH1-BH4 discovered
• GPX4 is critical but not alone

Present: Integration

• Understanding how multiple systems work together
• Context-dependent reliance on different pathways
• Therapeutic strategies targeting multiple defenses

Therapeutic Strategies Involving GPX4

For Cancer (Inhibit GPX4):

Monotherapy:

• Direct GPX4 inhibitors
• GSH depletion strategies
• System xc⁻ blockade

Combination Therapy:

• GPX4 inhibition + FSP1 inhibition
• GPX4 inhibition + GCH1 inhibition
• Triple blockade for maximum effect
• Combination with traditional chemotherapy

Precision Medicine:

• Biomarker testing: which cancers are GPX4-dependent?
• Identifying tumors with low alternative defenses
• Patient selection for ferroptosis-inducing therapies

For Neurodegeneration/Ischemia (Enhance GPX4):

Genetic Enhancement:

• Gene therapy to increase GPX4 expression
• Delivered to affected tissues

Pharmacological Support:

• Selenium supplementation
• Promoting endogenous GPX4 expression (NRF2 activators)
• Providing alternative ferroptosis defenses

Metabolic Support:

• Ensuring adequate GSH synthesis (NAC supplementation)
• Supporting reducing capacity (NADPH generation)
• Nutritional optimization

Key Challenges and Open Questions

Scientific Questions:

• How do cells decide which ferroptosis defense system to rely on?
• What determines GPX4 expression levels in different cell types?
• Can we predict GPX4 dependency in individual patients’ tumors?
• How do alternative pathways compensate for GPX4 loss?
• What are the long-term consequences of partial GPX4 inhibition?

Therapeutic Challenges:

• Achieving tumor-selective GPX4 inhibition
• Overcoming resistance to GPX4-targeting therapies
• Delivering GPX4-enhancing strategies to the brain
• Balancing efficacy and safety in all approaches
• Understanding optimal combination strategies

Key Takeaways

GPX4 stands as the central guardian against ferroptosis:

• It uniquely reduces membrane lipid hydroperoxides, preventing ferroptotic death
• GPX4 depends on glutathione, linking it to cysteine import and GSH synthesis
• It’s essential for life—complete loss is embryonically lethal
• Multiple isoforms protect different cellular compartments
• Direct GPX4 inhibition is a powerful ferroptosis trigger
• Cancer cells are often GPX4-dependent, making it a therapeutic target
• The brain relies heavily on GPX4 for protection against ferroptosis
• Alternative defenses (FSP1, GCH1) can partially compensate but not fully replace GPX4
• Understanding GPX4 is foundational to understanding ferroptosis

GPX4 exemplifies how a single enzyme can be the linchpin of a complex biological process. Its discovery as the master regulator of ferroptosis transformed our understanding of cell death and opened new therapeutic avenues across oncology, neurology, and beyond. While we now appreciate that cells have multiple ferroptosis defense systems, GPX4 remains the most critical—the first line of defense and the most common point of vulnerability.